At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 731 enrolled
Drug / intervention
FKB238 (bevacizumab) +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomised, Parallel, Double Blinded Study to Compare the Efficacy and Safety of FKB238 to Avastin® In 1st Line Treatment for Patients With Advanced/Recurrent Non Squamous NSCLC in Combination of Paclitaxel and Carboplatin
In Brief
A Phase 3 clinical trial evaluating FKB238 (bevacizumab), Avastin (bevacizumab), and 2 other interventions for Carcinoma, Non-Small-Cell Lung. Completed, enrolled 731 participants across 147 sites in 24 countries.
Detailed Summary
The purpose of this research study is to compare the effectiveness and safety of FKB238 against Avastin® in men and women with advanced/recurrent non squamous non-small cell lung cancer
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCarcinoma, Non-Small-Cell Lung
CountriesBelarus, Bosnia and Herzegovina, Bulgaria, Croatia, Georgia, Germany, Greece, Hungary, Italy, Japan, Peru, Philippines, Poland, Romania, Russia, Serbia, South Korea, Spain, Taiwan, Thailand, Turkey (Türkiye), Ukraine, United States, Vietnam
Collaborators--
Timeline
Phase 3CompletedFinished
2017201820192020202120222023202420252026
First PostedJun 2016
Enrollment StartSep 2016
Primary CompletionJan 2019
Study CompletionJan 2022
TodayJul 2026
First PostedJun 23, 2016
Enrollment StartSep 7, 2016
Primary CompletionJan 24, 2019
Study CompletionJan 26, 2022
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 10.0 years ago
Interventions
FKB238 (bevacizumab)drug
Avastin (bevacizumab)drug
Paclitaxeldrug
Carboplatindrug